Treatment of AD animal model (ADLPAPT) brains and AD patient-derived brain organoids with CKD-504, a histone deacetylase-6 (HDAC6) inhibitor, could significantly degrade pathological tau plaques. This evidence concerns the gene HDAC6 and Alzheimer disease.